Uplizna (Inebilizumab-cdon)

Uplizna (Inebilizumab-cdon

Uplizna

Inebilizumab-cdon

Injection: 100 mg/10 mL (10 mg/mL) solution in a single-dose vial

Horizon Therapeutics

Medical Use

Uplizna is a CD19-directed cytolytic antibody used to treat neuromyelitis optica spectrum disorder (NMOSD) in adults who test positive for AQP4 antibodies.

-Recommended Dosage:

  • -Pre-treatment Screening: Conduct screenings for Hepatitis B virus (HBV), quantitative serum immunoglobulins, and Tuberculosis (TB) before the first dose of Uplizna.
  • -Pre-infusion Requirements: Before each infusion, check for active infections and premedicate patients with a corticosteroid, an antipyretic, and an antihistamine.

-Administration:

  • -Dilution: Dilute Uplizna in 250 mL of 0.9% Sodium Chloride Injection before administration.
  • -Infusion: Administer as an intravenous (IV) infusion over approximately 90 minutes.

-Dosage Schedule:

  • -Initial Dose: 300 mg IV infusion, followed by a second 300 mg IV infusion 14 days later.
  • -Maintenance Dose: Starting six months after the initial dose, administer a single 300 mg IV infusion every six months.

-Monitoring: Closely monitor patients throughout the infusion and for at least 60 minutes after completion.